A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
Overview
Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG) that is taken-up by active cells such as cancer cells. This contrast can then be seen in the body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can produce "false positive" signals from the colon. Our hypothesis is that much of this signal comes from bacteria that are present in high concentrations in the colon. If this is the case, using an antibiotic to suppress the activity of bacteria may improve the ability of PET-CT to distinguish abnormal cells from normal cells in the colon.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Diagnostic
- Masking: None (Open Label)
- Study Primary Completion Date: October 2012
Interventions
- Drug: Rifaximin
- 550mg BID for 2 days
Arms, Groups and Cohorts
- Experimental: Rifaximin
- No Intervention: Control
- Randomly-selected matched PET-CT scans performed on same day as intervention group.
Clinical Trial Outcome Measures
Primary Measures
- SUVmax of FDG in Each Colonic Segment
- Time Frame: Day 2
Secondary Measures
- SUVavg in Each Colonic Segment
- Time Frame: Day 2
Participating in This Clinical Trial
Inclusion Criteria
- Patients undergoing clinically-indicated PET-CT scan for non-GI lymphoma Exclusion Criteria:
- Patients with known Inflammatory Bowel Disease – Patients with known colon cancer
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Collaborator
- Bausch Health Americas, Inc.
- Provider of Information About this Clinical Study
- Principal Investigator: Alan C. Moss, Assistant Professor of Medicine – Beth Israel Deaconess Medical Center
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.